甲羟孕酮治疗去势抵抗型前列腺癌的疗效观察  

Efficacy of medroxyprogesterone acetate treatment of castrate-resistant prostate cancer

作　　者：沈志勇[1] 王玲[1] 程惠华[1] 付志超[1] 廖绍光[1] 骆华春[1] 雷勇[2] 

机构地区：[1]福州总医院,厦门大学附属东方医院放疗科,福建福州350025 [2]福州总医院,厦门大学附属东方医院医务部,福建福州350025

出　　处：《现代肿瘤医学》2017年第2期246-248,共3页Journal of Modern Oncology

摘　　要：目的:观察甲羟孕酮对于去势抵抗型前列腺癌(CRPC)的疗效及毒副反应。方法:观察62例CRPC患者口服甲羟孕酮后,对比口服药物前后PSA、生活质量KPS评分、血红蛋白、营养状况的变化,评价药物毒副反应。结果:62例患者经过口服甲羟孕酮后,PSA下降的有效率为11.3%、稳定率达24.2%。KPS评分、血红蛋白较前明显改善(P值均<0.05)。营养状况的改善率为64.5%、稳定率达30.6%。未发现III-IV级毒副反应,6例出现轻度低钠血症,5例出现轻度低钾血症,Ⅰ度下肢水肿较治疗前增加4例。结论:甲羟孕酮可延缓部分CRPC患者的PSA进展,改善晚期肿瘤患者的生活质量,毒副反应小。Objective：To observe the efficacy and side effects of medroxyprogesterone in castrate-resistant prostate cancer（ CRPC）.Methods：PSA,KPS score,hemoglobin,nutritional status,and drug toxicity were evaluated in 62 CRPC patients before and after orally taking medroxyprogesterone.Results：After orally taking medroxyprogesterone,PSA decreased in 7 patients（ 11.3%）,and remained stable in 15 patients（ 24.2%）.KPS score and hemoglobin were improved significantly（ P〈0.05）.The nutritional status were improved in 40 patients（ 64.5%）,and remained stable in 19 patients（ 30.6%）.No III-IV grade toxic and side effects were found.Six patients had mild hyponatremia,five patients had mild hypokalemia,four patients had Ⅰdegree lower limb edema after treatment.Conclusion：Medroxyprogesterone may slow the progression of the PSA,improve the quality of life with few drug side effects in advanced CRPC patients.

关 键 词：甲羟孕酮 去势抵抗型前列腺癌 生活质量 疗效 

分 类 号：R737.25[医药卫生—肿瘤]